Osteoporosis induced by chronic glucocorticotherapy – treatment and prophylaxis
Keywords:
osteoporosis, glucocorticotherapy, bisphosphonateAbstract
Glucocorticoids as strong anti-inflammatory and anti-immunosuppressive drugs are used in the treatment of many inflammatory and autoimmune etiology diseases. These illnesses usually demand prolonged glucocorticoid therapy what is a reason of many adverse events occurrence with osteoporosis as a one of the most important. Glucocorticoids lead to osteoporosis development by reduction of bone formation and by increase of bone resorption. Therapy and prophylaxis of glucocorticoid-induced osteoporosis is focused on minimize of bone loss, as a consequence of corticoids administration, and prevention of life threatening bone fractures. The aim of this paper is a review of literature concerning osteoporosis induced by chronic glucocorticotherapy, its treatment possibilities and prophylaxis as well as current recommendations of preferred therapy regimens.
Downloads
References
Adler RA, Rosen CJ., Glucocorticoids and osteoporosis, Endocrinol Metab Clin North Am 1994; 23: 641.
Manolagas SC, Weinstein RS., New developments in the pathogenesis and treatment of steroid-induced osteoporosis, J Bone Miner Res 1999; 14: 1061.
MacAdams MR, White RH, Chipps BE., Reduction of serum testosterone levels during chronic glucocorticoid therapy, Ann Intern Med 1986; 104: 648.
Pearce G, Tabensky DA, Delmas PD, Baker WH, Seeman E., Corticosteroid-induced bone loss in men, J Clin Endocrinol Metab 1998; 83: 801.
Manolagas SC, Weinstein RS., New developments in the pathogenesis and treatment of steroid-induced osteoporosis, J Bone Miner Res 1999; 14: 1061.
Bressot C, Meunier PJ, Chapuy MC., Histomorphometric profile, pathophysiology, and reversibility of corticosteroid-induced osteoporosis, Metab Bone Dis Rel Res 1979; 1: 303.
Kaji H, Sugimoto T, Kanatani M, Nishiyama K, Chihara K., Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E-2, J Bone Miner Res 1997; 12: 734.
Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA., Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease, Ann Intern Med 1994; 120: 207.
Rubin MR, Bilezikian JP., Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 2002; 87: 4033.
Reid IR, Heap SW., Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 1990; 150: 2545.
Kanis JA, Johansson H, Oden A, Johnell O, de Lacet C, Melton III LJ, et al., A meta-analysis of prior corticosteroid use and fracture risk, J Bone Miner Res 2004; 19: 893.
van Staa TP, Leufkens HG, Cooper C., The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis, Osteoporos Int 2002; 13: 777.
Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G., Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica, BMJ 1986; 293: 1463
Wang WQ, Ip MS, Tsang KW, Lam KS., Antiresorptive therapy in asthmatic patients receiving high-dose inhaled steroids: a prospective study for 18 months, J Allergy Clin Immunol 1998; 101: 445.
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis, Arthritis Rheum 2001; 44: 1496.
Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM., Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis, Ann Intern Med 1996; 125: 961.
Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen, Pocock N, et al., Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin, N Engl J Med 1993; 328: 1747.
Lukert BP, Raisz LG., Glucocorticoid-induced osteoporosis: pathogenesis and management, Ann Intern Med 1990; 112: 352.
Adams JS, Wahl TO, Lukert BP., Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients, Metabolism 1981; 30: 217.
LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA, George LK, et al., Thiazide diuretic agents and the incidence of hip fracture, N Engl J Med 1990; 322: 2860.
Cauley JA, Cummings SR, Seeley DG, Black D, Browner W, Kuller LH, et al., Effects of thiazide diuretic therapy on bone mass, fractures, and falls. Ann Intern Med 1993; 118: 666.
Jones G, Nguyen T, Sambrook PN, Eisman JA., Thiazide diuretics and fractures: can meta-analysis help?, J Bone Miner Res 1995; 10: 106.
Felson DT, Sloutskis D, Anderson JJ, Anthony JM, Kiel DP., Thiazide diuretics and the risk of hip fracture. Results from the Framingham study, JAMA 1991; 265: 370.
MacAdams MR, White RH, Chipps BE., Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104: 648.
Lukert BP, Johnson BE, Robinson RG., Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992; 7: 1063.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al., Risks and benefits of estrogen and progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial, JAMA 2002; 288: 321.
Reid IR, Wattie DJ, Evans MC, Stapleton JP., Testosterone therapy in glucocorticoid-treated men, Arch Intern Med 1996; 156: 1173.
Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ., Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring longterm systemic glucocorticoid treatment, J Clin Endocrinol Metab 2003; 88: 3167.
Reid IR, King AR, Alexander CJ, Ibbertson HK., Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate APD). Lancet 1988; 1: 143.
Reid IR, Heap SW, King AR, Ibbertson HK., Two-year follow-up of bisphosphonate (APD) treatment in steroidinduced osteoporosis, Lancet 1988; 2: 1144.
Gallacher SJ, Fenner JAK, Anderson K, Bryden FM, Banham SW, Logue FC, et al., Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study, Thorax 1992; 47: 932.
Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP., Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone, J Bone Miner Res 2001; 16:104 - 12.
Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al., Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis, N Engl J Med 1998; 339: 292.
Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al., Risedronate therapy prevents corticosteroid-induced bone loss, Arthritis Rheum 1999; 42: 2309.
Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al:, Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis, N Engl J Med 1997; 337: 382.
Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizatto G., Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991; 49: 71.
Lane NE, Sanchez S, Modin GW, Genant HK, Ini E, Arnaud CD., Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial, J Clin Invest 1998; 102: 1627.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2006 Medical Journal of the Rzeszow University
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
